I

n a setback for the pharmaceutical industry, the Nevada state assembly on Thursday voted in favor of a controversial bill aimed at lowering prices for diabetes medicines. The legislation, which passed the state senate last week, now goes to Governor Brian Sandoval.

The bill is designed to lower costs by requiring drug makers to report pricing histories, disclose costs, and notify state officials and insurers in advance of price hikes above inflation. And a recently added amendment would also require drug companies to disclose rebates paid to pharmacy benefit managers, the middlemen that negotiate favorable insurance coverage.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi Ed I am out of pocket until after Memorial Day. I would Contact Genia Long at Analysis Group about CRADAs . She is more up to date than me Henry

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X